JaLCDOI 10.18926/AMO/54603
FullText URL 70_5_409.pdf
Author Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune|
Abstract Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
Keywords Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD
Amo Type Clinical Study Protocols
Publication Title Acta Medica Okayama
Published Date 2016-10
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 409
End Page 412
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777437
Web of Science KeyUT 000388098700014
Title Alternative An investigator initiated phase II clinical trial of tamibarotene (AM80G) for chronic graft-versus-host disease
FullText URL 127_133.pdf
Author Nishimori, Hisakazu| Maeda, Yoshinobu|
Keywords 臨床研究中核病院 慢性GVHD タミバロテン 同種造血幹細胞移植 Th17
Publication Title 岡山医学会雑誌
Published Date 2015-08-03
Volume volume127
Issue issue2
Start Page 133
End Page 137
ISSN 0030-1558
Related Url isVersionOf https://doi.org/10.4044/joma.127.133
language Japanese
Copyright Holders Copyright (c) 2015 岡山医学会
File Version publisher
DOI 10.4044/joma.127.133
NAID 130005096255
Author Sugiyama, Haruko| Maeda, Yoshinobu| Nishimori, Hisakazu| Yamasuji, Yoshiko| Matsuoka, Ken-ichi| Fujii, Nobuharu| Kondo, Eisei| Shinagawa, Katsuji| Tanaka, Takehiro| Takeuchi, Kengo| Teshima, Takanori| Tanimoto, Mitsune|
Published Date 2014-02
Publication Title Biology of Blood and Marrow Transplantation
Volume volume20
Issue issue2
Content Type Journal Article
Author Kurimoto, Etsuko| Miyahara, Nobuaki| Kanehiro, Arihiko| Waseda, Koichi| Taniguchi, Akihiko| Ikeda, Genyo| Koga, Hikari| Nishimori, Hisakazu| Tanimoto, Yasushi| Kataoka, Mikio| Iwakura, Yoichiro| Gelfand, Erwin W.| Tanimoto, Mitsune|
Published Date 2013-01-20
Publication Title Respiratory Research
Volume volume14
Content Type Journal Article
Title Alternative Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophages
FullText URL 126_1.pdf
Author Miyamoto, Satoshi| Shikata, Kenichi| Miyasaka, Kyoko| Okada, Shinichi| Sasaki, Motofumi| Kodera, Ryo| Hirota, Daisho| Kajitani, Nobuo| Takatsuka, Tetsuharu| Kataoka Usui, Hitomi| Nishishita, Shingo| Horiguchi Sato, Chikage| Funakoshi, Akihiro| Nishimori, Hisakazu| Uchida, Haruhito Adam| Ogawa, Daisuke| Makino, Hirofumi|
Keywords cholecystokinin 糖尿病性腎症 抗炎症作用 腎保護効果
Publication Title 岡山医学会雑誌
Published Date 2014-04-01
Volume volume126
Issue issue1
Start Page 1
End Page 6
ISSN 0030-1558
Related Url http://www.okayama-u.ac.jp/user/oma/
language Japanese
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
DOI 10.4044/joma.126.1
JaLCDOI 10.18926/AMO/49251
FullText URL 67_1_1.pdf
Author Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune|
Abstract Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th17 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.
Keywords chronic GVHD Th17 Am80 regulatory T cell (Treg) steroid-refractory
Amo Type Review
Publication Title Acta Medica Okayama
Published Date 2013-02
Volume volume67
Issue issue1
Publisher Okayama University Medical School
Start Page 1
End Page 8
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2013 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 23439503
Web of Science KeyUT 000316829900001
Author Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune|
Published Date 2012-12-03
Publication Title 岡山医学会雑誌
Volume volume124
Issue issue3
Content Type Journal Article